Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Director William Grieco sold 2,000 shares of the stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $51.71, for a total value of $103,420.00. Following the transaction, the director now directly owns 45,013 shares in the company, valued at approximately $2,327,622.23. The transaction was disclosed in a filing with the SEC, which is available at this link.

William Grieco also recently made the following trade(s):

  • On Friday, June 16th, William Grieco sold 2,000 shares of Acadia Healthcare stock. The stock was sold at an average price of $45.42, for a total value of $90,840.00.

Acadia Healthcare Company, Inc. (ACHC) traded down 0.40% during midday trading on Monday, reaching $52.17. The company’s stock had a trading volume of 667,802 shares. The company has a 50 day moving average of $50.42 and a 200-day moving average of $44.84. Acadia Healthcare Company, Inc. has a 1-year low of $32.54 and a 1-year high of $54.34. The company has a market capitalization of $4.58 billion, a P/E ratio of 573.30 and a beta of 1.15.

Acadia Healthcare (NASDAQ:ACHC) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.66 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. Acadia Healthcare had a return on equity of 8.69% and a net margin of 0.30%. The business had revenue of $715.90 million for the quarter, compared to analysts’ expectations of $717.38 million. During the same quarter in the previous year, the firm posted $0.73 earnings per share. The company’s revenue was down 5.4% compared to the same quarter last year. Equities research analysts anticipate that Acadia Healthcare Company, Inc. will post $2.45 earnings per share for the current fiscal year.

WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/14/acadia-healthcare-company-inc-nasdaqachc-director-sells-103420-00-in-stock.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in Acadia Healthcare by 65.6% in the second quarter. BlackRock Inc. now owns 8,523,077 shares of the company’s stock valued at $420,871,000 after buying an additional 3,377,291 shares during the period. JPMorgan Chase & Co. boosted its position in Acadia Healthcare by 0.8% in the first quarter. JPMorgan Chase & Co. now owns 7,705,975 shares of the company’s stock valued at $335,980,000 after buying an additional 59,735 shares during the period. Vanguard Group Inc. boosted its position in Acadia Healthcare by 8.9% in the second quarter. Vanguard Group Inc. now owns 6,254,532 shares of the company’s stock valued at $308,849,000 after buying an additional 511,299 shares during the period. Aristotle Capital Management LLC acquired a new position in Acadia Healthcare during the first quarter valued at approximately $140,071,000. Finally, FMR LLC boosted its position in Acadia Healthcare by 26.4% in the second quarter. FMR LLC now owns 2,775,451 shares of the company’s stock valued at $137,052,000 after buying an additional 580,449 shares during the period.

Several research firms recently issued reports on ACHC. Craig Hallum reissued a “buy” rating and set a $65.00 target price (up previously from $52.00) on shares of Acadia Healthcare in a research note on Monday, July 31st. Zacks Investment Research lowered Acadia Healthcare from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. UBS AG reissued a “positive” rating and set a $60.00 target price (up previously from $54.00) on shares of Acadia Healthcare in a research note on Monday, July 31st. Mizuho increased their target price on Acadia Healthcare from $57.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Finally, BidaskClub raised Acadia Healthcare from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $59.21.

About Acadia Healthcare

Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.

Insider Buying and Selling by Quarter for Acadia Healthcare (NASDAQ:ACHC)

Receive News & Ratings for Acadia Healthcare Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.